Pfizer and Bioatla have licensed each other’s technology platforms to develop ADCs with Conditionally Active Biologic (CAB) antibodies as the payload delivery vehicles.
An Israeli researcher says a cost-effective method for making human liver cells offers drug developers better safety evaluation and will “undoubtedly” replace animal testing.
Scientists trying to curb malaria deaths usually concentrate on preventing mosquito bites or developing human vaccines and therapies, but novel gene-editing tool CRISPR is opening up another path.
Abzena is set to buy The Chemistry Research Solution (TCRS) in a deal one analyst says shows the firm’s intentions to dominate the bio-conjugation space.
A professor who conducted fast-track trials during last year’s Ebola outbreak says next time such trials must be part of humanitarian response… because there will be a next time.
Dyadic has agreed to sell its enzyme-producing fungal expression system and the rest of its industrial technology business to DuPont for $75 million (€70 million).
The UK biopharma industry is reporting difficulties finding manufacturing workers with the skills to make vaccines, biologics, and advanced therapy medicinal products (ATMP), according to ABPI.
A successful HIV vaccine will have to induce several broadly neutralising antibodies to mimic some patients’ immune response to HIV infection, according to the Duke Human Vaccine Institute.
An expanded San Diego facility will support demand for preclinical and clinical development services driven by the growth in the antibody and biosimilar sector, Intertek says.
A UK firm has launched a searchable database of genomic data from sources all over the world that it says will accelerate development of personalised medicines.
Austin Community College has received a Government grant to establish a centre for biotechnology technicians it hopes will provide skilled workers for the Texas biomanufacturing industry.
Demand for biopharmaceutical testing is in part responsible for higher capacity utilisation but, despite encouraging signs, it is too early to say if preclinical pricing will improve accordingly says Envigo.
AZ’s MedImmune and a Mitsubishi pharma subsidiary are set to collaborate on creating next-generation ADCs using pyrrolobenzodiazepine (PBD)-based warheads.
Cobra Biologics, a Swedish contract development and manufacturing organisation, has launched a project to improve scale-up of biologics with the University of Manchester, UK.
Danish biotech Bavarian Nordic has signed a $9m contract from Johnson & Johnson to improve stability of their joint Ebola vaccine. After options and milestone awards, payment could total $33m.
Trial supplies of a radio-immunotherapy drug made by Areva Med in compliance with GMP are stable five years after they were produced according to the results of new analysis.
Influenza research completed just before the US banned ‘gain-of-function’ studies could help vaccine makers boost virus yields and accelerate production say scientists.
A bispecific antibody developed by Roche subsidiary Chugai has been granted Breakthrough Therapy Designation by the US FDA for the treatment of haemophilia A.
German biotech Immatics and the University of Texas have spent $60m on spin-out Immatics US to specialise in adoptive cellular therapies (ACT) for cancer.
The US Department of Agriculture (USDA) has filed a complaint against antibody supplier Santa Cruz Biotechnology for its allegedly poor treatment of animals.
Roche has added technology to tailor enzymes for specific applications in next-generation DNA and RNA sequencing through the acquisition of Kapa Biosystems.
